In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
|Articles|October 27, 2021
Pharmacy Clinical Pearl of the Day: Breast Cancer
Author(s)Saro Arakelians, PharmD
After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Advertisement
Clinical Pearl of the Day: Breast Cancer
Breast cancer is a cancer that forms in the cells of the breasts.
Insight:
- After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
- Breast cancer can occur in both men and women, but it's far more common in women.
- Symptoms include a breast lump or thickening that feels different; change in the size, shape, or appearance of the breast; a newly inverted nipple; peeling, scaling, crusting or flaking of the pigmented area of skin; and redness or pitting of the skin.
- Risk factors include being female, increasing age, history of breast cancer, family history, obesity, and having a child at an older age.
- Diagnostic tools may include breast exam, mammogram, breast ultrasound, biopsy, and MRI.
- Treatment includes lumpectomy, mastectomy, sentinel node biopsy, axillary lymph node dissection, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and palliative care.
- Chemotherapy can be given before surgery (neoadjuvant) or after surgery (adjuvant).
- Adjuvant and neo-adjuvant drug may include anthracyclines, such as doxorubicin (Adriamycin), epirubicin (Ellence); taxanes such as paclitaxel (Taxol) and docetaxel (Taxotere), 5-Fluorouracil (5-FU) or capecitabine, cyclophosphamide (Cytoxan), and carboplatin.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
3
Using CKDintercept to Build Interdisciplinary Kidney Care
4
2026 AHA Endocarditis Guidelines Expand Outpatient Antibiotic Options
5